Article in Basic & clinical pharmacology & toxicology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
Gensheng WangApplied Toxicology Program, Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA.
Julie A HuttGreenfield Pathology Services, Inc., Greenfield, Indiana, USA.
Guodong WuApplied Toxicology Program, Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA.
Stephen M KaminskyWeill Cornell Medicine, Belfer Gene Therapy Core Facility, New York, New York, USA.
Sara CramWeill Cornell Medicine, Belfer Gene Therapy Core Facility, New York, New York, USA.
Rajeshkumar BarurDivision of Cardiovascular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
J Kevin DonahueDivision of Cardiovascular Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Lovelace Respiratory Research Institute · USCornell University · USUniversity of Massachusetts Chan Medical School · USGreenfield Community College · US
Funding
Focal Modification of Electrical Conduction in the HeartR01HL067148 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DONAHUE, J KEVIN · 2002 to 2011
$3.7M
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillationR33HL158541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN, MCMANUS, DAVID D. · 2022 to 2023
$3.4M
Calcium and MAPKinase Signaling and Structural Remodeling in Atrial FibrillationR01HL158143 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN · 2021 to 2024
$3.2M
Final preclinical development of AAV gene therapy for atrial fibrillationR01HL130376 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN · 2016 to 2019
$2.9M
GENE TRANSFER APPROACHES TO ATRIAL FIBRILATIONR01HL093486 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN · 2008 to 2012
$2.0M
PURPOSE OF THE NGVB CONTRACT IS TO CONTINUE SUPPORTING GENE THERAPY RESEARCH.75N92019D00018 · OD · INDIANA UNIVERSITY INDIANAPOLIS · 2019 to 2023
$1.7M
Improved Methods for Myocardial Gene TransferR01EB002846 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI DONAHUE, J KEVIN · 2003 to 2005
$883k
Preclinical gene therapy development for post-operative atrial fibrillationR21AG042701 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN · 2013 to 2014
$442k
A phase I trial of AdKCNH2-G628S gene therapy for post-op atrial fibrillationR61HL158541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DONAHUE, J KEVIN, MCMANUS, DAVID D. · 2021 to 2021
$419k
REGULATION OF THE BIOSYNTHESIS OF THE OPIOID PEPTIDES AND OTHER NEUROPEPTIDESZ01HL000018 · NHLBI · HEART, LUNG, AND BLOOD INSTITUTE · PI SABOL, S L · 1985 to 1992
Post-operative atrial fibrillation (POAF) is the most common complication after cardiac surgery. Despite implementation of several pharmacological strategies, incidence of POAF remains at approximately 30%. An adenovirus vector encoding KCNH2-G628S has proven efficacious in a porcine model of AF. In this preclinical study, 1.5 × 10
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Preclinical safety and biodistribution assessment of Ad-KCNH2-G628S administered via atrial painting in New Zealand white rabbits. · full record | OpenQuestion